CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

CASI Pharmaceuticals Trading Down 3.3 %

CASI stock opened at $3.20 on Friday. The company has a market cap of $42.88 million and a PE ratio of -1.58. The stock has a 50-day moving average price of $4.90 and a two-hundred day moving average price of $4.90. CASI Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $8.48.

Hedge Funds Weigh In On CASI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CASI. Renaissance Technologies LLC acquired a new stake in CASI Pharmaceuticals in the 3rd quarter valued at $27,000. Susquehanna International Group LLP raised its holdings in CASI Pharmaceuticals by 70.6% in the fourth quarter. Susquehanna International Group LLP now owns 57,395 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 23,758 shares in the last quarter. Citigroup Inc. bought a new position in CASI Pharmaceuticals during the 1st quarter valued at $59,000. Finally, Virtu Financial LLC grew its holdings in CASI Pharmaceuticals by 39.6% during the 1st quarter. Virtu Financial LLC now owns 112,777 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 31,971 shares in the last quarter. Hedge funds and other institutional investors own 22.23% of the company’s stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.